PEN Stock - Penumbra, Inc.
Unlock GoAI Insights for PEN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.19B | $1.06B | $847.13M | $747.59M | $560.41M |
| Gross Profit | $755.00M | $682.64M | $535.21M | $475.38M | $338.18M |
| Gross Margin | 63.2% | 64.5% | 63.2% | 63.6% | 60.3% |
| Operating Income | $9.28M | $73.55M | $6.08M | $-7,501,000 | $-38,942,000 |
| Net Income | $14.01M | $90.95M | $-2,002,000 | $5.28M | $-15,702,000 |
| Net Margin | 1.2% | 8.6% | -0.2% | 0.7% | -2.8% |
| EPS | $0.36 | $2.37 | $-0.05 | $0.07 | $-0.54 |
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | JP Morgan | Upgrade | Overweight | $370 |
| December 11th 2025 | Citigroup | Upgrade | Buy | $350 |
| November 18th 2025 | Wells Fargo | Initiation | Underweight | $15 |
| October 8th 2025 | Needham | Upgrade | Buy | $326 |
| September 2nd 2025 | Evercore ISI | Initiation | Outperform | $300 |
| March 14th 2025 | BofA Securities | Initiation | Buy | $320 |
| January 21st 2025 | UBS | Initiation | Buy | $305 |
| December 17th 2024 | Oppenheimer | Initiation | Outperform | $275 |
| December 11th 2024 | Wells Fargo | Upgrade | Overweight | $275← $190 |
| September 18th 2024 | Stifel | Initiation | Buy | $238 |
| September 3rd 2024 | Leerink Partners | Initiation | Outperform | $263 |
| July 31st 2024 | Wells Fargo | Downgrade | Equal Weight | $150← $289 |
| July 31st 2024 | Citigroup | Downgrade | Neutral | $178← $165 |
| February 23rd 2024 | JP Morgan | Downgrade | Neutral | $250← $284 |
| September 6th 2023 | Morgan Stanley | Initiation | Equal Weight | $265 |
Earnings History & Surprises
PENEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 21, 2026 | — | — | — | — |
Q1 2026 | Feb 17, 2026 | $1.11 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.93 | $0.97 | +4.4% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $0.81 | $0.86 | +6.2% | ✓ BEAT |
Q2 2025 | Apr 23, 2025 | $0.66 | $0.83 | +25.8% | ✓ BEAT |
Q1 2025 | Feb 18, 2025 | $0.88 | $0.97 | +10.2% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $0.69 | $0.85 | +23.2% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $0.56 | $0.64 | +14.3% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.42 | $0.41 | -2.4% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | $0.71 | $0.76 | +7.0% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.46 | $0.67 | +45.7% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $0.28 | $0.43 | +53.6% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $0.11 | $0.23 | +109.1% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $0.14 | $0.16 | +14.3% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.01 | $0.01 | +19.6% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.07 | $0.01 | +114.3% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $0.06 | $-0.01 | -116.7% | ✗ MISS |
Q1 2022 | Feb 22, 2022 | $0.19 | $0.10 | -47.4% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $0.14 | $0.12 | -14.3% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $0.17 | $0.21 | +23.5% | ✓ BEAT |
Latest News
Truist Securities Maintains Buy on Penumbra, Raises Price Target to $370
📈 PositiveJP Morgan Upgrades Penumbra to Overweight, Raises Price Target to $370
📈 PositiveCanaccord Genuity Maintains Buy on Penumbra, Raises Price Target to $359
📈 PositiveNeedham Maintains Buy on Penumbra, Raises Price Target to $388
📈 PositiveCitigroup Upgrades Penumbra to Buy, Raises Price Target to $350
📈 PositiveWatching Penumbra; Hearing Investor Business Daily SwingTrader Buys Stock
📈 PositiveCanaccord Genuity Maintains Buy on Penumbra, Raises Price Target to $355
📈 PositivePenumbra shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositivePenumbra shares are trading higher after the company beat Q3 estimates and raised FY2025 sales guidance.
📈 PositivePenumbra shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositivePenumbra Raises FY2025 Sales Guidance from $1.355B-$1.370B to $1.375B-$1.380B vs $1.366B Est
📈 PositivePenumbra Q3 Adj. EPS $0.97 Beats $0.92 Estimate, Sales $354.685M Beat $340.795M Estimate
📈 PositivePenumbra Presents STORM-PE Results At VIVA 2025; Trial Data Shows CAVT Plus Anticoagulation Improves Functional Outcomes Than Anticoagulation Alone In PE Patients
📈 PositiveNeedham Reiterates Buy on Penumbra, Maintains $326 Price Target
📈 PositiveBTIG Reiterates Buy on Penumbra, Maintains $320 Price Target
📈 PositiveTruist Securities Maintains Buy on Penumbra, Lowers Price Target to $300
📈 PositiveNeedham Upgrades Penumbra to Buy, Announces $326 Price Target
📈 PositiveEvercore ISI Group Maintains Outperform on Penumbra, Lowers Price Target to $285
➖ NeutralEvercore ISI Group Initiates Coverage On Penumbra with Outperform Rating, Announces Price Target of $300
📈 PositivePenumbra Appoints Shruthi Narayan As President, Effective Sept. 1
➖ NeutralFrequently Asked Questions about PEN
What is PEN's current stock price?
What is the analyst price target for PEN?
What sector is Penumbra, Inc. in?
What is PEN's market cap?
Does PEN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PEN for comparison